Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.44 |
| ▸ | WNT3A | P56704 | 14/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727207 | 0.89 | ESR2 (0.44) | GLSWNT3ALMNAGLAMAPK1 | |
| SCHEMBL3731644 | 0.89 | DGAT1 (0.47) | GLSLMNAGLAMAPK1NOD2 | |
| SCHEMBL3724802 | 0.88 | ESR2 (0.46) | GLSLMNAGLAMAPK1NOD2 | |
| SCHEMBL3734829 | 0.88 | LMNA (0.51) | GLSLMNAGLAMAPK1NOD2 | |
| SCHEMBL3731029 | 0.86 | SIRT2 (0.45) | GLSLMNAGLAMAPK1NOD2 | |
| SCHEMBL3740010 | 0.86 | RXFP1 (0.53) | GLSLMNAGLAMAPK1NOD2 | |
| SCHEMBL3733053 | 0.85 | LMNA (0.48) | GLSWNT3ALMNAGLAMAPK1 | |
| SCHEMBL3728807 | 0.85 | ESR2 (0.43) | GLSWNT3ALMNAGLAMAPK1 | |
| SCHEMBL3733735 | 0.84 | ESR2 (0.47) | LMNAGLAMAPK1NOD2ESR2 | |
| SCHEMBL3733264 | 0.84 | GLS (0.44) | GLSLMNAGLAMAPK1NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | BOUILLOT ANNE MARIE JEANNE | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | GLS 737/4885WNT3A 2482/4885LMNA 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.